Skip to main content
Premium Trial:

Request an Annual Quote

EU Regulators Approve Jurilab, Nanogen s Drug Metabolism Chip as IVD

NEW YORK, May 2 (GenomeWeb News) - European regulators have granted CE Mark approval to Jurilab and Nanogen's DrugMet drug-metabolizing enzyme microarray, the companies said today.

 

The firms can now sell the product in the European Union for clinical use as an in vitro diagnostic.

 

Launched in 2004 as a research-use product, DrugMet is designed to detect variation in genes including CYP2D6, CYP2C9, and CYP2C19, as well as duplication and deletion of the CYP2D6 gene.

 

In July, Nanogen paid €1.25 million ($1.5 million) for a 25-percent stake in Jurilab.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.